Nitric Oxide Releasing Nasal Spray for SARS-CoV-2 Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19 caused by SARS-CoV-2 face challenges due to the virus's high contagiousness and the instability and reactivity of nitric oxide (NO), making it difficult to store and administer effectively for therapeutic purposes.
Innovation Solution
A nitric oxide releasing solution (NORS) is developed, which includes a nitric oxide releasing compound and an acidifying agent, forming a solution that releases NO as a nasal spray (NONS), providing a controlled and extended release of NO to effectively treat and prevent SARS-CoV-2 infections by reducing viral load and blocking viral access to host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitric oxide is used for therapeutic purposes, then antiviral effectiveness is improved, but stability and ease of storage are worsened
Solution Approach 1:
The patent applies preliminary action by pre-combining nitric oxide with a carrier material to form a stable composite formulation before administration. This allows the reactive nitric oxide to be prepared in advance and stored stably, then activated at the time of use to achieve therapeutic effects without degradation during storage.
Solution Approach 2:
The patent uses a carrier material as an intermediary substance that mediates between the unstable nitric oxide and the biological system. The carrier protects nitric oxide from degradation while enabling controlled release and delivery to the target site, thus maintaining both stability during storage and effectiveness during treatment.
2Reliability
If nitric oxide is administered for therapeutic purposes, then antiviral effectiveness is improved, but ease of administration is worsened
Solution Approach 1:
The carrier material serves as an intermediary delivery vehicle that simplifies administration by encapsulating nitric oxide in a stable, easily administrable formulation. This allows the potent but difficult-to-administer nitric oxide to be delivered through conventional routes without requiring specialized handling equipment or procedures.
Solution Approach 2:
The patent changes the physical and chemical parameters of nitric oxide by combining it with a carrier material, transforming it from a gas requiring specialized delivery into a stable formulation that can be administered through conventional medical routes, thus improving ease of administration while maintaining therapeutic effectiveness.
3Reliability
If nitric oxide is used to treat infections, then viral load reduction is improved, but difficulty in transport is worsened
Solution Approach 1:
The patent applies preliminary action by preparing nitric oxide in a pre-stabilized composite formulation with a carrier material that can be manufactured and stored in advance. This eliminates the need for specialized transport conditions required for pure nitric oxide gas, allowing easy manufacturing and transport while maintaining the ability to achieve viral load reduction when activated.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The NORS effectively reduces SARS-CoV-2 viral load by up to 99% within 72 hours, providing a therapeutic benefit in treating and preventing COVID-19, with no adverse health events recorded in clinical trials, and offers a safe, self-administered treatment option.
Implementation Method 1
a nitric oxide releasing solution (NORS) can include at least one nitric oxide releasing compound and at least one acidifying agent
Implementation Method 2
the NORS can provide release (e.g., an extended release) of gaseous nitric oxide (gNO) when administered to a situs
Data Source
AI summary
The present disclosure is drawn to methods and compositions for treating infections and minimizing transmissibility. The method can comprise treating a subject for infection with Severe Acute Respiratory Syndrome Coronavirus (SARSr-CoV) comprising administering a therapeutically effective amount of a nitric oxide releasing solution (NORS) to the subject. The NORS can be administered as a spray having an average droplet volume which contains treatment within the upper respiratory tract. The method of minimizing subject-to-subject transmissibility for a pathogen can comprise administering a therapeutically effective amount of a nitric oxide releasing solution (NORS) to the subject. NORS can include at least one nitric oxide releasing compound and acidifying agent, which can release a therapeutically effective amount of spray having an average droplet volume which contains treatment within the upper respiratory tract.